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We analysed the expression of cyclins A2, B1, D1, and E1 by immunohistochemistry and numerical aberrations in CCND1 gene by
fluorescence in situ hybridization technique in 67 primary oral squamous cell carcinomas (OSCC). Cyclin A2 expression was
observed in 54 (83.1%) tumours, cyclin D1 in 58 (89.2%), cyclin B1 in 39 (60%), and cyclin E in 21 (32.8%). CCND1 region
analysis revealed 26 (43.3%) tumours with the presence of numerical aberrations which were correlated with cyclin D1 high
expression (Rho = 0.48; p < 0 001). Twenty-nine (45.3%) tumours were classified as high proliferative tumours assessed by Ki-67
protein expression and correlated with tumours with high expression of cyclin A2 (Rho = 0.30; p = 0 016) and cyclin B1
(Rho = 0.37; p = 0 003). In multivariate analysis for an overall five-year survival (OS), we found an adverse independent
prognostic value for cyclin A2 high expression (p = 0 031) and for advanced tumour stage (p < 0 001). Our results confirm that
several cyclins are commonly expressed in OSCC. CCND1 gene is abnormal in more than one-third of the cases and is
frequently associated with cyclin D1 high expression. Moreover, cyclin A2 high expression is an independent indicator of worse
OS suggesting that this protein may serve as a reliable biological marker to identify high-risk subgroups with poor prognosis.
1. Introduction
Oral cancer remains a significant cause of morbidity and
mortality, with 529,451 new cases and 292,289 estimated
deaths annually worldwide in 2012 [1]. Over 90 percent
of cancers of the oral cavity are represented by oral squa-
mous cell carcinomas (OSCC). Despite technological
advances in the detection and management of oral cancer
during the last few decades, many centres still report low
survival rates (~50%) [2].
It is believed that oral carcinogenesis involves a series of
genetic alterations that frequently involve normal cell cycle
control proteins such as cyclins and their enzymatically
active partners, the cyclin-dependent kinases (CDK) [3, 4].
The discovery of major proteins involved in these alterations
could identify new molecular markers that may serve as
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prognostic markers of OSCC and help in developing more
precise treatment plans for these cancers [3, 5].
Cyclins are divided into two groups based on their func-
tion: the G1 cyclins (C, D, and E), regulating the passage of
cells through the G1 phase and their entry into the S phase,
and the mitotic cyclins (A, B) [3, 6]. The CCND1 is a
proto-oncogene located in chromosome 11q13 that encodes
cyclin D1. This protein binds and activates CDK4 and
CDK6, leading to phosphorylation of pRb driving the cell
cycle from the G1 to the S phase. CCND1 amplification and
overexpression have been reported to be frequent events in
several tumours including head and neck cancers [7, 8].
Several studies have reported the correlation between cyclin
D1 overexpression and CCND1 amplification, lymph node
metastasis, local recurrence, advanced histological grade
(G2/G3), and poor survival [9, 10]. Cyclin A is required for
DNA synthesis during the S phase and progression through
the G2/M transition. Cyclin A overexpression has been found
to be an adverse prognostic factor in oral premalignant and
malignant lesions [6, 11, 12]. Cyclin E is expressed in the
middle of the G1 phase and ends at the beginning of the S
phase. High levels of cyclin E1 may lead to accelerated G1/S
transition and in an elongated S phase duration, resulting
in an increased chromosomal instability [13]. Overexpres-
sion of cyclin E1 has been reported in several cancers includ-
ing nasopharyngeal carcinomas with an influence on
prognosis [14]. Cyclin B1 is crucial to drive epithelial cells
into the mitosis phase. Uncontrolled cyclin B1 expression
may result in premature entry into mitosis, abnormal cell
proliferation, and neoplastic transformation. Cytoplasmic
overexpression of cyclin B1 has been reported in several can-
cers including head and neck cancers and is related with
advanced histological grade and local recurrence of these
cancers [15].
The aim of the current study was to evaluate the expres-
sion of cyclins A2, B1, D1, and E1 and CCND1 gene status in
a single cohort of patients with oral squamous cell carcino-
mas (OSCC) and relate them to clinical-pathologic charac-
teristics and patient outcome.
2. Patients and Methods
2.1. Patient Population. In this observational study, we
included 67 patients newly diagnosed and treated for primary
OSCC (ICD: C01–06) at the Clinical University Hospital of
Santiago de Compostela (CUHSC) (Spain), between 1995
and 2003. The study was undertaken following the approval
of the institutional ethical board of the hospital and
performed in accordance with the Declaration of Helsinki.
We followed the methods of Monteiro et al. [16]. Briefly,
clinical information was obtained from the patient’s records,
including gender, age of the patient, tumour site, stage
classification (7th edition of American Joint Committee on
Cancer) [17], treatment performed (Table 1), surgical margin
status, and follow-up information. On a new 4μm
hematoxylin-eosin (HE) section, we revaluated histological
diagnosis, tumour differentiation grade (WHO 2005) [18],
and the presence of vascular or perineural invasion (Table 1).
2.2. Immunohistochemistry. The immunohistochemical
techniques were performed on tissue microarrays (TMA),
constructed according to a previously described method
[16, 19]. For this, two cores (1.5mm each) from previously
selected tumoural areas of each patient were used resulting
in three TMA blocks with 134 cores.
For immunohistochemical staining, 4μm sections from
TMA blocks were used. After deparaffinization and rehydra-
tion, slides were treated for antigen retrieval and incubated
with the primary antibodies listed in Table 2. Visualization
was performed using the dextran-polymer system (EnVi-
sionTM Detection Kit, Dako, Glostrup, Demark) and
Table 1: Patient characteristics (N = 67).




Age (mean age: 59± 12.6 years) <59 years 33 (49.3%)
≥59 years 34 (50.7%)
Location
Tongue 28 (41.8%)
Floor of the mouth 20 (29.9%)
Gingiva 7 (10.4%)
Retromolar trigone 4 (6.0%)
Hard palate 5 (7.5%)























Free of tumour 54 (85.7%)







SG: surgery; RT: radiotherapy (consisting in adjunctive external-beam
radiotherapy, 55-66Gy). ∗Patients were excluded if they had undergone
radiotherapy or chemotherapy prior to surgery. None of the included
patients received molecular therapies against EGFR or other proteins. ∗∗Not
available in 4 cases. Table 1 is reproduced from Monteiro et al. [16]
(under the Creative Commons Attribution License/Public Domain).
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counterstaining with Harris hematoxylin for 2min. For each
staining run, we used positive (tonsil) and negative (omission
of primary antibody) controls.
2.3. Evaluation of Immunohistochemistry Expression. Two
observers (L.M. and M.F.) analysed the immunohistochemi-
cally stained slides using an Olympus BX41 microscope,
blinded to the clinical characteristics of the tumours. Any
discordant case was reviewed under a multihead microscope
to achieve a final result. We considered the highest score of
the two core disks.
The expression of cyclins was semiquantitatively evalu-
ated on the basis of the extent of nuclear tumour cell staining
for cyclin A2, cyclin D1, and cyclin E and cytoplasm tumour
cell staining for cyclin B1. This expression was classified on a
four-point score: negative (no labelling or labelling in <10%
of tumour cells); 1+ (labelling in 10% to 24% of tumour cells);
2+ labelling in 25% to 49% of tumour cells); and 3+ (labelling
in 50% or more of tumour cells). In the following high
expression, thresholds were used as cut-offs: 25% for cyclin
A2, 50% for cyclin D1, and 10% for cyclin B1 and cyclin
E1. These cut-offs were determined for each cyclin based
on the mean of the expression score for each marker (high
value than the mean score was considered high expres-
sion) (adapted from Sawair et al. [20]). In this way, a
score of 2+/3+ was considered as a high expression for
cyclin A2 (mean score of 1.4± 0.9), a score of 3+ for cyclin
D1 (mean score of 2.3± 1.1), and any score of 1+/2+/3+ for
cyclin E1 (mean score of 0.8± 0.7) and cyclin B1(mean score
of 0.4± 0.7).
For Ki-67 evaluation, we considered two groups based
on nuclear staining of tumour cells: low proliferative
tumour (labelling from 0 to 49% of tumour cells) and high
proliferative tumour (labelling in 50% or more of tumour
cells) [21].
2.4. Fluorescence In Situ Hybridization. The detection of
11q13 band was carried out by fluorescence in situ hybridiza-
tion technique. Briefly, the procedure was as follows:
Slides were dried overnight at 55°C for 20 minutes.
After deparaffinization and rehydration, the slides were
placed in saline sodium citrate (SSC2x) wash for 3
minutes in a water bath. Paraffin-embedded sample pre-
treatment was carried out with a sodium thiocyanate
(NaSCN) 1M, at 80°C for 30 minutes. Afterwards, the
slides were placed in distilled water for 1 minute and in
SSC2x for 5 minutes.
To perform the enzymatic digestion protocol, we used
0.05mg/mL pepsin solution in HCl 0.01N. Enzyme activity
for the various sections taken from each specimen was
stopped at different times by slide immersion in SSC2x for
1 minute and tissue drying in a thermal plate at 45°C. Tissue
appearance was then observed under light microscopy with
10x and 40x magnification. Optimal tissue digestion was
achieved when the tissue showed fern-like formations under
light microscopy. After this, the slides were placed in 2 baths
of SSC2x for 3 minutes and dehydrated. Then the slides were
air dried at room temperature for 15 minutes.
Probe mix was carried out according to the manufac-
turer’s specifications using the probe CCND1 FISH DNA
Probe Split signal (Y5414) (DakoCytomation, Glostrup,
Denmark). Hybridization was performed on the DakoCyto-
mation Hybridizer (DakoCytomation Glostrup, Denmark),
first at 84°C for 5 minutes and finally at 37°C overnight. For
posthybridization washes, we used SSC0.4x with 0.3% Noni-
det P-40 (NP-40) at 73°C for 3 minutes. Then the slides were
placed in SSC2x with 0.1% NP-40 at room temperature.
Afterwards, the slides were air dried for 20 minutes and
mounted in DAPI II (4′-6′-diamidino-2-feniloide) counter-
stain from Vysis Inc. (Downers Grove, IL).
2.5. Evaluation of Fluorescence In Situ Hybridization. Image
analysis was performed using an Eclipse E400 Nikon fluores-
cence microscope (Nikon, Tokyo, Japan) equipped with
DAPI (nuclei) and Spectrum Green/Spectrum Orange dual
band pass filter sets (magnification of 400x). We considered
the presence of CCND1 numerical aberrations when at least
20% of the nuclei exhibited 3 or more signals for CCND1 in
high-power fields [22].
2.6. Statistical Analysis. Possible relations between categorical
variables were analysed using chi-square tests. The correla-
tion between protein markers was measured by Spearman’s
correlation coefficient. Time interval (expressed in months)
between primary treatment and last follow-up or death of
the patient corresponded to overall survival (OS). Time
interval (expressed in months) between primary treatment
and the first recurrence (whether local, regional or distant)
corresponded to disease-free survival (DFS). Univariate anal-
ysis of the influence of markers on five-year OS and DFS was
performed using the Kaplan-Meier and the log-rank test.
Factors that were significant in the univariate analysis were
then analysed by multivariate analysis using the Cox propor-
tional hazards model.
Table 2: Primary antibodies used in the present study.
Antibody Clone Dilution Pretreatment Manufacturer
Anti-Ki-67 MIB-1 1/200 WB+TE DakoCytomation, Glostrup, Denmark
Anti-cyclin D1 SP4 Prediluted WB Master Diagnostica, Spain
Anti-cyclin E1 13A3 1/50 WB Novocastra Leica Biosystems, Newcastle upon Tyne, UK
Anti-cyclin A2 6E6 1/10 WB Novocastra Leica Biosystems, Newcastle upon Tyne, UK
Anti-cyclin B1 7A9 1/10 WB Novocastra Leica Biosystems, Newcastle upon Tyne, UK
WB: waterbath at 98°C 30 minutes; TE: tris-ethylenediaminetetraacetic acid (EDTA).
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The level of statistical significance was considered
at p < 0 05.
3. Results
3.1. Cyclin A2. Of the 134 cores of the cyclin A2 slides, 13
(9.70%) cores could not be analysed: 8 (5.97%) cores con-
tained no tumour cells, 4 (2.99%) were lost, and 1 (0.75%)
had not sufficient cells for scoring. In the view of this, 2
(2.99%) out of 67 cases could not be analysed for cyclin A2.
The cyclin A2 expression was observed in 54 (83.1%)
cases (Figures 1(a) and 1(b)), classified as 1+ in 29 (44.6%),
2+ in 15 (23.1%), and 3+ in 10 (15.4%).
3.2. Cyclin B1. Out of 134 core disks, 10 (7.46%) cores could
not be evaluated for cyclin B1: 8 (5.97%) contained no
tumour cells, 1 (0.75%) was lost during processing, and
1 (0.75%) had not sufficient cells for scoring, resulting
the elimination of 2 (2.99%) cases.
The cyclin B1 expression was observed in 39 (60%)
cases (Figures 1(c) and 1(d)), classified as 1+ in 29
(44.6%) and 2+ in 10 (15.4%).
3.3. Cyclin D1. Out of 134 core disks, 10 (7.46%) cores could
not be analysed for cyclin D1: 8 (5.97%) contained no
tumour cells, 1 (0.75%) was lost during processing, and
1 (0.75%) had not sufficient cells for scoring resulting the
elimination of 2 (2.99%) cases.
The cyclin D1 expression was observed in 58 (89.2%)
cases (Figures 1(e) and 1(f)), classified as 1+ in 6 (9.2%),
2+ in 13 (20%), and 3+ in 39 (60%).
3.4. Cyclin E1. Out of 134 core disks for cyclin E1, 13 (9.7%)
cores could not be analysed: 9 (6.72%) contained no tumour
cells, 3 (2.24%) were lost during processing, and 1 (0.75%)
had not sufficient cells for scoring. Therefore, 3 (4.48%) out
of 67 cases could not be analysed for cyclin E1.
The cyclin E1 expression was positive in 21 (32.8%) cases
(Figures 1(g) and 1(h)), classified as 1+ in 15(23.4%) and
2+ in 6 (9.4%).
3.5. Ki-67. In tissue microarray slides stained for Ki-67, 12
(8.96%) cores could not be evaluated: 7 (5.22%) contained
no tumour cells, 4 (2.99%) had too few cells for scoring,
and 1 (0.75%) was lost during processing. Because of this, 3
cases (4.47%) could not be analysed at all.
Ki-67 expression was detected in almost all cases (61,
95.3%) except in three. Twenty-nine (45.3%) cases were
classified as high proliferative tumours and 35 (54.7%) as
low proliferative tumours (Figures 1(i) and 1(j)).
3.6. CCND1 Gene Analysis. Out of 134 core disks, 14 (10.4%)
could not be evaluated for CCND1 analysis: 8 (5.97%)
contained no tumour cells and 6 (4.5%) were lost during
processing. Therefore, 7 (10.5%) out of 67 cases could not
be analysed for CCND1 gene analysis.
Inassessing theCCND1gene,we found that43.3%(n = 26)
of the cases showed the presence of numerical aberrations
(Figures 1(k) and 1(l)). In 19 cases (31.7%), there were more
than six signals or cluster formations present per nuclei.
3.7. Association of High Expression of Markers with
Clinicopathological Features. The presence of high expres-
sion of cyclin A2 (in 25% or more of tumour cells) was asso-
ciated with male gender (p = 0 023), more advanced T
category (p = 0 003), and/or more advanced tumour stage (
p = 0 002). The presence of high expression of Ki-67 was
associated with more advanced T category (p = 0 003), with
more advanced tumour stages (p = 0 006), and with the pres-
ence of vascular invasion (p = 0 016). All cases with vascular
invasion were high proliferative tumours.
None of the other markers (cyclin B1, D1, or E1
and CCND1 gene status) were correlated with clinico-
pathological features.
3.8. Coexpression of Markers of the Study.High Ki-67 expres-
sion was observed in tumours with high expression of cyclin
A2 (Rho=0.30; p = 0 016) and cyclin B1 (Rho=0.37;
p = 0 003). High expression of cyclin A2 was correlated with
high expression of cyclin B1 (Rho=0.32; p = 0 009).
Tumours with cyclin D1 high expression (in 50% or more
of tumour cells) reached a significant relationship with the
existence of numerical aberrations (Rho= 0.48; p < 0 001).
3.9. Patients’ Outcome. Patients were observed for a mini-
mum of 3 years after treatment or until their death. During
the follow-up period, 36 (53.7%) had died of oral cancer.
Overall survival rate at 5 years of follow-up was 49.4%, and
DFS was 34%. In univariate analysis, T status (p < 0 001),
N status (p < 0 001), clinical stage (p < 0 001), perineural per-
meation (p = 0 039), and cyclin A2 expression (p = 0 005)
(Figure 2) were statistically correlated to OS (Table 3). The
same was observed with reference to DFS for T status
(p < 0 001), N status (p < 0 001), clinical stage (p < 0 001),
and tumour grade (p = 0 007) (Table 3).
In multivariate analysis for OS, we only found an inde-
pendent prognostic value for stage and cyclin A2 expression
(Table 4), where tumours with advanced stage (p < 0 001)
and with high expression of cyclin A2 (p = 0 031) had
lower OS (Table 4). For DFS, advanced stage (p < 0 001)
and histological differentiation grade (p = 0 006) presented
adverse independent prognostic value in the multivariate
analysis (Table 4).
4. Discussion
Deregulation and aberrations of cell cycle-related cyclins
have been implicated in the tumour growth and progression
of several cancers [3, 5]. The understanding of these
alterations in tumorigenesis may identify new proteins that
may serve as important cancer diagnostic and prognostic
indicators as well as potential targets for therapeutic
approaches in patients with OSCC [16, 23]. With this in
mind, we conducted this study to evaluate the influence of
the expression of the cyclins A2, B1, D1, and E1 and CCND1
gene status on clinical, pathologic, and prognostic charac-
teristics of patients with OSCC.
Cyclins were highly expressed in the present cohort of
OSCC. Cyclin D1 was present in almost 90% of the cases
and highly expressed in 60% being the most detected cyclin
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in these tumours. This is in line with the reported high
expression of this protein in OSCC [8, 21, 24]. High
expression values were also noted for cyclin A2, observed
in more than 80% of tumour cells, and lower frequencies
were observed for cyclins B1 and E1. These levels of
expression are in accordance with the reported literature
for these proteins reflecting the relevant role of these pro-
teins in OSCC [6, 11, 13, 25].
Several clinical and pathological indicators of the tumour
progression, such as tumour size, nodal metastasis, clinical
stage, and histological grade, have been related with cyclin





Figure 1: Immunohistochemical staining of cyclins and CCND1 region analysis by fluorescence in situ hybridization technique in OSCC. (a)
Low expression for cyclin A2 (magnification ×200). (b) High expression for cyclin A2 (magnification ×200). (c) Low expression for cyclin B1
(magnification ×200). (d) High expression for cyclin B1 (magnification ×200). (e) Low expression for cyclin D1 (magnification ×200). (f)
High expression for cyclin D1 (magnification ×200). (g) Low expression for cyclin E1 (magnification ×200). (h) High expression for cyclin
E1 (magnification ×200). (i) Low expression for Ki-67 (magnification ×200). (j) High expression for Ki-67 (magnification ×200). (k)
Normal CCND1 numerical signals (magnification ×200). (l) Presence CCND1 numerical aberrations (magnification ×200).
5Analytical Cellular Pathology
contribution of cyclins in control of the cell cycle and thereby
tumour proliferation [6, 11, 22]. We could confirm the
associations of cyclin A2 with tumour size (T), nodal
metastasis, and the clinical stage suggesting that high
expression of cyclin A2 could be relevant for tumour pro-
gression and metastization. Chen et al. [11] observed a sig-
nificant association between high cyclin A2 expression and
advanced stage tumour, advanced tumour size (T), and
presence of nodal metastasis. Saarilahti et al. [6] reported
an association with histological grade.
To assess the relation of the expression of these cyclins
with proliferative tumour phenotype, we evaluated the
expression of the nuclear protein Ki-67, a proliferation
marker described in some studies as an indicator of aggres-
sive behaviour serving as a prognostic indicator [21]. In the
present work, high Ki-67 expression was detected in almost
half of the cases and related with T and clinical stage and also
with the presence of tumour vascular invasion. Interestingly,
Ki-67 was significantly associated with the expression of
cyclin A2 and cyclin B1 confirming the proliferative capacity
of these tumour cells. Other authors have also observed this
association between cyclin A2 and Ki-67 [6, 13, 26].
Cyclin D1 overexpression has been related with amplifi-
cation of the CCND1 gene in several tumours including
OSCC [22, 27, 28]. The activation of the pathways involved
in cyclin D1 expression appears to be essential in the devel-
opment of human cancers, including oral cancer [27]. In
view of this, we analysed the status of the 11q13 region where
this gene is located. We observed that 43.3% of the cases
presented aberration of this region with 6 or more signals
per cell in 32% cases. Similar values were reported by other
authors [7, 22, 29] in head and neck cancer.
Furthermore, we observed a significant association of
CCND1 status with cyclin D1 high expression. These results
suggest that overexpression of cyclin D1 could be caused by
numerical aberrations in the 11q13 region such as CCND1
amplification. Nevertheless, there were some cases with
cyclin D1 high expression that presented a normal 11q13 sta-
tus. This suggests that mechanisms other than amplification
of CCND1 gene could be involved in overexpression of this
cyclin including increasing mRNAs, decrease in cyclin D
proteolytic degradation or DNA methylation [30, 31].
An important aspect of a molecular marker is the relation
of the marker with the prognosis of the patient. We observed
that OSCC patients with high expression of cyclin A2 in their
cell tumours presented a significantly lower 5-year overall
survival even in multivariate survival analyses, indicating
that cyclin A2 expression could be an independent prognos-
tic marker in OSCC. Chen et al. [6], evaluating squamous cell
carcinomas of the oral cavity, found an association between
high cyclin A2 expression and lower overall survival. This
was also seen in the study of Saarilahti et al. [11], in addition
to the association with disease-free survival although in
laryngeal carcinomas. Thomson et al. [32] observed an
association of cyclin A expression with the recurrence of
the disease in malignant and premalignant lesions of the oral
cavity. Cyclin A is required for DNA synthesis during the S
phase and progression through the G2/M transition. Our
results suggest that tumours with cyclin A2 expression will
drive the cells to division thus rendering them some growth
potential. This will influence the survival/death of the tumour
in patients with overexpression of this protein marker. In our
series, no other cyclins or markers studied were significantly
related with survival. Nevertheless, some studies reported
the influence of other cyclins such as cyclin D1 [8, 10, 22,
29, 30, 33] or cyclin B1 [25] on the prognosis of OSCC. Some
recent papers have suggested the influence of CCND1 ampli-
fication on a poor overall survival and cervical nodal metasti-
zation which led us to evaluate not only the protein
expression of cyclin A2 but also the CCND1 region status
[7, 9, 22].We could not find an association of numerical aber-
rations in the 11q13 region such as CCND1 amplification
with any clinical and pathological variables such as nodal
metastasis and also with survival. This could be due to the
small size of our series, differences in tumour sites [7], or
possible differences in geographic populations [8, 10]. Our
data indicate that for South European populations, cyclin
A2 is a major prognostic marker, being an indicator of high
proliferative status tumours but importantly also of a poor
patient’s survival with these tumours. This can assist oncolo-
gists in the planning treatment options for each patient with
OSCC, indicating better and more adjusted chemotherapy
or radiotherapy protocols considering the cyclin A2 status
of the tumours [34, 35]. Moreover, these proteins could
function as targets for molecular therapies against this
pathway leading to chronic mitotic arrest and cell death by
apoptosis [36]. Our findings thus could have a translational




























Figure 2: Univariate Kaplan-Meier analysis of overall survival in
patients with OSCC. Patients with tumours with high expression
of cyclin A2 presented a lower survival rate than patients with low
expression of cyclin A2.
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Table 3: Univariate analysis of overall survival and disease-free survival at 5 years, according to clinicopathological characteristics and marker
expression.
Factor Group N Overall survival (5 years) p value N∗∗ Disease-free survival (5 years) p value
Gender
Female 15 64.2 0.206 14 50
0.442
Male 52 47.3 50 30.7
Age
<59 years 33 44.4 0.500 33 30.6
0.534






Floor of the mouth 20 44.4 20 25
Gingiva 7 28.6 5 40
Retromolar trigone 4 50 3 33.3
Hard palate 5 80 5 20





<0.001T2 27 53.2 27 30.5
T3 6 33.3 6 22.2





<0.001N1 11 9.1 10 12





<0.001II 20 67.8 20 43.3
III 11 27.3 11 21.2











0.011G2 29 36.1 28 27.2
G3 4 25 4 0
Margin status∗




















































Numerical aberration 26 47.1 25 29.7
SG: surgery; RT: radiotherapy. ∗Not available in 4 cases. ∗∗The number of patients in the disease-free survival in some of the analyses is different from the overall
survival analysis as some patients had persistence of the disease and were only evaluated in the overall survival.
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Nevertheless, we wish to highlight some limitations of
the present study, related with its retrospective nature that
sometimes could not give the range of variables and infor-
mation that prospective studies could give.
In conclusion, we report high expression of cell
cycle-related proteins such as cyclin D1 and cyclin A2
in OSCC. Importantly, we found an independent prog-
nostic value for cyclin A2 protein in OSCC indicating
a poor overall survival for patients with tumours with
high expression of cyclin A2. The present study suggests
that this protein could serve as a prognostic marker
in OSCC.
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